Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06686472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 13, 2024 (before its estimated December 10, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Trial Details
NCT Number NCT06686472
Lead Sponsor Telios Pharma, Inc.
Conditions
(from sponsor)		 Allergic Conjunctivitis
Related terms Conjunctivitis, Allergic
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov